# 1 High sensitivity of a novel rapid test for the diagnosis of clinical and subclinical *Plasmodium*

# 2 *falciparum* infections in a high transmission setting in Burundi

- 3
- 4 David Niyukuri<sup>1</sup>, Denis Sinzinkayo<sup>1,2</sup>, Emma Troth<sup>3</sup>, Colins Oduma<sup>4</sup>, Mediatrice Barengayabo<sup>1</sup>, Mireille
- 5 Ndereyimana<sup>1</sup>, Aurel Holzschuh<sup>3</sup>, Claudia A. Vera-Arias<sup>3</sup>, Yilekal Gebre<sup>3</sup>, Kingsley Badu<sup>5</sup>, Joseph
- 6 Nyandwi<sup>1,6</sup>, Dismas Baza<sup>7</sup>, Elizabeth Juma<sup>8</sup>, Cristian Koepfli<sup>3\*</sup>
- 7
- 8 <sup>1</sup> Doctoral School, University of Burundi, Bujumbura, Burundi
- 9 <sup>2</sup> National Malaria Control Program, Bujumbura, Burundi
- <sup>3</sup> Eck Institute for Global Health and Department of Biological Sciences, University of Notre Dame, Notre
- 11 Dame, USA
- 12 <sup>4</sup>Kenya Medical Research Institute, Kisumu, Kenya
- 13 <sup>5</sup> Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
- <sup>6</sup> National Institute of Public Health, Bujumbura, Burundi
- <sup>7</sup>WHO Country office, Bujumbura, Burundi
- 16 <sup>8</sup>WHO African Region, Accra, Ghana
- 17
- 18 \*Corresponding author: <u>ckoepfli@nd.edu</u>

19

## 21 Abstract

22 Rapid diagnostic tests (RDTs) are a key tool for the diagnosis of malaria infections among febrile and 23 subclinical individuals. Low-density infections, and deletions of the P. falciparum hrp2/3 genes (encoding 24 for the HRP2 and HRP3 proteins detected by many RDTs) present challenges for RDT-based diagnosis. 25 The novel Rapigen Biocredit three-band Plasmodium falciparum HRP2/LDH RDT was evaluated among 26 444 febrile and 468 subclinical individuals in a high transmission setting in Burundi. Results were 27 compared to the AccessBio CareStart HRP2 RDT, and qPCR with a sensitivity of <0.1 parasites/µL blood. 28 Sensitivity among clinical patients was 80.0% (250/313, either of HRP2/LDH positive), compared to 29 73.2% (229/313) for CareStart (P=0.048). Among subclinical infections, sensitivity was 72.3% (162/224) 30 compared to 58.5% (131/224) for CareStart (P=0.003), and reached 88.3% (53/60) in children <15 years. 31 No (0/362) hrp2 and 2/366 hrp3 deletions were observed. In conclusion, the novel RDT showed improved 32 sensitivity for the diagnosis of P. falciparum.

#### 34 Introduction

35

36 Accurate diagnosis and treatment of malaria infections is a key pillar for control. Over the last decade, 37 rapid diagnostic tests (RDTs) have become widely used for diagnosis. RDTs are lateral flow devices that 38 detect parasite-specific proteins by immunohistochemistry. No laboratory infrastructure is required for 39 RDT use, they can be used with minimal training, and results are available within 10-20 minutes [1, 2]. 40 The sensitivity of RDTs for the diagnosis of clinical cases is similar or better than light microscopy, the 41 only other method for diagnosis in health centers. RDTs are used in many peripheral health centers 42 where microscopy is not available, and by community health workers. In 2020, nearly 300 million RDTs 43 were used by malaria control programs [3].

44

In addition to clinical infections diagnosed at health centers, subclinical infections present a major challenge for transmission. While not causing febrile illness, subclinical infections can result in more subtle health impacts, e.g. anemia [4]. Using different approaches, several studies found that over 50% of transmission originates from asymptomatic infections [5-7]. A study conducted in western Kenya estimated 95% of transmission stemming from subclinical carriers [8]. RDTs are the key diagnostic tool for strategies to target the subclinical reservoir, for example through active [9, 10] or reactive case detection [11, 12],

52

Among clinical and subclinical infections, a proportion of infections are below the limit of detection of RDTs and remain untreated. These untreated infections might result in extended periods of illness, and sustain onward transmission. More sensitive RDTs might be needed to achieve further gains in malaria control and elimination.

57

Apart from low parasite density, deletions of the *hrp2* and *hrp3* genes are a threat to diagnosis by RDT. The most sensitive RDTs for *P. falciparum* detect the HRP2 and HRP3 proteins. Deletions of these genes have been initially described in Peru [13] and later in multiple countries, and result in false-negative RDTs even when parasite density is high. In Africa, deletions are particularly prevalent around the Horn of Africa

62 [14-16], and have been described in multiple other countries, e.g. the Democratic Republic of Congo [17], 63 and Ghana [18]. Alternative diagnostic targets include Plasmodium Lactate Dehydrogenase (pLDH) or 64 Aldolase. These proteins are essential and thus genes cannot be deleted, but sensitivity of diagnosis is 65 lower compared to HRP2 [19]. The WHO recommends regular surveillance of *hrp2/hrp3* deletion to select 66 the optimal tool for diagnosis [20].

67

68 Burundi experiences among the highest levels of malaria transmission globally [21, 22]. In contrast to the 69 trend in many other countries in sub-Saharan Africa, the number of cases has increased in the last two 70 decades [22]. The increase was observed despite an increase in the number of health centers offering 71 diagnosis and treatment, and increase in testing, and roll-out of interventions such as bed nets and indoor 72 residual spraying (IRS) [22]. To understand the benefit a novel, highly sensitive RDT, suspected febrile 73 cases presenting to a health center, and subclinical community members were tested by the novel RDT, 74 an established RDT, and results compared to highly sensitive gPCR. P. falciparum positive infections 75 were typed for hrp2 and hrp3 deletions.

- 76
- 77

## 78 Study Population and Methods

79

#### 80 Ethical approval

81 Informed written consent was collected from each individual, or, in the case of minors, from the legal 82 guardian prior to sample collection. This study was approved by the Comité National d'Ethique pour la 83 protection des êtres humains sujets de la recherche biomédicale et comportementale of Burundi 84 (approval no. CNE/03/2021), and the University of Notre Dame Institutional Review Board (approval no. 85 21-02-6446).

86

#### 87 Rapid diagnostic tests

The Biocredit Malaria Ag Pf (pLDH/HRPII) RDT, manufactured by Rapigen, contains two test bands, one for HRP2 and one for LDH, in addition to the control band. Plasmodium Lactate Dehydrogenase (pLDH)

is an enzyme of the glycolytic pathway and essential for the parasite. Histidine Rich Protein 2 and 3 are
 highly expressed proteins. Their function is not well understood [2]. Deletions of the *hrp2* and *hrp3* genes
 result in false-negative RDTs.

93 Given the separated HRP2 and LDH bands, the test can be used for surveillance of possible *hrp2* 94 deletion. Differences in sensitivity of HRP2 and LDH can be studied using a single test. This test meets 95 critical WHO criteria and is currently undergoing WHO prequalification [23].

96

As comparison, the AccessBio CareStart Malaria Pf (HRP2) RDT was used. This HRP2-based RDT has
been in use for approximately ten years [24-26]. It is the main RDT used by health systems in multiple
African countries [18, 27].

100

## 101 Sample collection and RDT diagnosis

102 Burundi experiences high, vear-round transmission of P. falciparum malaria with moderate seasonality. 103 Samples were collected in Cibitoke Province in northwestern Burundi. Cibitoke Province borders Rwanda 104 and the Democratic Republic of Congo (DRC). Samples were collected during the dry, lower transmission 105 season in June 2021. Clinical samples were collected in health centers. All patients presenting for malaria 106 diagnosis were invited to join the study. Subclinical samples were collected on a market, with all 107 individuals present invited to join the study. Demographic data of study participants are given in Table 1. 108 Due to the convenience sampling strategy, the study population does not represent the general 109 population. Only 27/468 subclinical individuals were children below 5 years of age, and only 73/468 were 110 children aged 5-15 years. The majority of those sampled were female.

- 111
- 112
- . . .
- 113
- 114
- 115
- 116
- 117

# 118

			Test positivity		Test positivity		RDT	
Clinical		Ν	by qPCR	Р	by RDT	Р	sensitivity	Р
Age group	0-5	158	62.0%		49.4%		72.4%	
	5-15	99	82.8%	0.002	86.9%	<0.001	96.3%	<0.001
	>15	187	71.1%		58.3%		75.2%	
Gender	Male	181	67.4%		62.7%		82.0%	
	Female	263	72.6%	0.236	59.7%	0.514	78.5%	0.460
			Durana ku		During laws a here		DDT	
			Prevalence by	_	Prevalence by	_	RDT	_
Subclinical		Ν	qPCR	P	RDT	Р	sensitivity	Р
Age group	0-5	27	51.8%		55.6%		78.6%	
	5-15	73	63.0%	0.015	67.1%	<0.001	91.3%	0.003
	>15	368	44.7%		36.8%		66.5%	
				1		I		i.
Gender	Male	217	50.7%		39.6%		75.5%	
	Female	250	45.6%	0.272	46.1%	0.158	69.3%	0.303

119

120 **Table 1**: Demographics of study population and risk factors for infection (by qPCR and RDT). For RDT data, results 121 from the Biocredit test were included, with either band (HRP2 or LDH) positive counting as a positive test. Test 122 positivity and prevalence by RDT includes individuals that were RDT positive but qPCR negative, resulting in higher 123 test positivity or prevalence by RDT than qPCR in some groups. RDT sensitivity is calculated as proportion of RDT 124 positive individuals among those positive by qPCR.

125

Approximately 200 µL blood was collected by finger prick into EDTA tubes. Two RDTs were run on site.
 Remaining blood was stored at -20°C until DNA extraction.

128

## 129 *P. falciparum* qPCR and *hrp2/3* deletion typing

130 DNA was extracted using the Macherey-Nagel NucleoMag Blood 200 µL kit according to manufacturer's 131 instructions. This kit yields very high DNA recovery, resulting in a low limit of detection [28]. DNA was 132 extracted from 200 µL blood and eluted in 100 µL elution buffer. qPCR was done in a total volume of 12 133 µL, including 2 µL DNA, corresponding to 4 µL blood. The P. falciparum varATS assay was used. This 134 assay targets a multicopy gene that is present in approximately 60 copies per parasite, of which 135 approximately 20 copies are amplified with the primers and probe used. It thus offers very high sensitivity 136 of <0.1 parasites/µL blood [29]. For absolute quantification of parasite density, a standard curve derived 137 from DNA from cultured 3D7 parasites and quantified by droplet digital PCR (ddPCR) was run along

samples. Samples positive for *P. falciparum* at a density of approximately >5 parasites/µL were typed for
 *hrp2* and *hrp3* deletion by ddPCR [30].

140

## 141 Data analysis

As parasite density distributions were skewed, geometric mean densities are given whenever densities are reported. To determine the limit of detection (LoD) of each RDT target, logistic regression analysis was conducted. LoD was defined as the lowest parasite density where a qPCR-positive infection would be detected with 95% probability. Cl95 = 95% confidence interval.

- 146
- 147

#### 148 **Results**


## 149 **RDT sensitivity and specificity**


444 febrile patients presenting to a health center were enrolled. By qPCR, *P. falciparum* positivity was
70.5% (313/444). Mean parasite density by qPCR was 727.4 parasites/µL (Cl95: 405.9, 1303.6).
Counting either band (HRP2 or LDH) positive, the sensitivity of the Biocredit RDT was 79.9% (250/313 of
infections detected, Figure 1A, Table 2). 23 individuals tested positive by RDT, but negative by qPCR,
resulting in a specificity of 82.4%.

		Clinical		Subclinical	
	LoD				
	[parasites/uL]	Sensitivity	Specificity	Sensitivity	Specificity
Biocredit any band	34	79.9%	82.4%	72.3%	84.4%
Biocredit HRP2	42	77.6%	90.1%	71.0%	88.1%
Biocredit LDH	290	71.9%	91.6%	50.0%	93.4%
CareStart HRP2	178	73.2%	96.2%	58.5%	93.4%

#### 155

156 **Table 2**: Sensitivity, specificity, and limit of detection of RDTs.





158

Figure 1: Correspondence among qPCR, and different RDTs and RDT targets. For panel A, when either band on the
 Biocredit RDT was positive it was recorded as positive. Panel B includes false-positive RDTs that were negative by
 qPCR.

162

Among 468 subclinical individuals enrolled, 47.9% (224/468) were positive by qPCR. Mean parasite
density was 22.9 parasites/µL (Cl95: 13.1, 40.3). The sensitivity of the Biocredit test was 72.3% (162/238,
Figure 1A, Table 2). 38 individuals were positive by RDT but negative by qPCR, resulting in a specificity
of 84.4% (194/230).


167

The novel Biocredit RDT was compared against the CareStart RDT, an established product routinely used in multiple countries (Figure 1A). The CareStart RDT showed a sensitivity of 73.2% (229/313) among clinical individuals and thus was slightly less sensitive than the Biocredit RDT with a sensitivity of 79.9% (P<0.001, Table 2). Five individuals tested positive by CareStartRDT but negative by qPCR, resulting in a specificity of 96.2%. Among subclinical individuals, sensitivity of the CareStart was 58.5% (131/224), and thus substantially lower than the Biocredit at 72.3%. Specificity was 93.4% (228/244, P<0.001, Table 2).

176 On the Biocredit RDT, the HRP2 band was more sensitive than the LDH band (Figure 1B). Among clinical 177 individuals, sensitivity of HRP2 was 77.6% (243/313), compared to 71.9% (225/313) for the LDH band 178 (P<0.001, Table 2). Specificity was 90.1% (118/131) for HRP2, and 91.6% (120/131) for LDH (Table 2). 179 Among subclinical individuals, the difference in sensitivity between HRP2 and LDH was more pronounced 180 than among clinical infections. Sensitivity of HRP2 was 71.0% (159/224), compared to 50.0% (112/224) 181 for LDH (P<0.001, Table 2). Specificity for HRP2 only was 88.1% (215/244), and for LDH only it was 182 93.4% (214/230, Table 2). Low correspondence between false-positive HRP2 and LDH bands was 183 observed. Among 61 false-positive RDTs (clinical and subclinical combined), only 8 were false-positive for 184 both targets, 34 were positive for HRP2 only, and 19 for LDH only.

185

The LoD, defined as the lowest parasite density that could be detected with 95% probability, was 34 parasites/µL (Cl95 17, 82) for the Biocredit RDT (any band), 42 parasites/µL (Cl95 22, 96) for the Biocredit HRP2 band, 290parasites/µL (Cl95 159, 617) for the Biocredit LDH band, and 178 parasites/µL (Cl95 94, 399) for CareStart (Table 2, Figure 2).



191	Figure 2: Limit of Detection (LoD) of each RDT and RDT target in relation to parasite density. Parasite density (by
192	qPCR) of RDT positive and RDT negative samples is shown along the top and bottom X-axis. Shaded lines show
193	95% confidence intervals. A) Biocredit (any band) B) Biocredit HRP2 C) Biocredit LDH D) CareStart HRP2
194	
195	hrp2/3 deletion typing
196	362 P. falciparum positive samples were successfully typed for hrp2 deletion, and 366 were successfully
197	typed for hrp3 deletion. No hrp2 deletions were observed. Two samples carried hrp3 deletion, one each
198	collected from a clinical and subclinical patient. The subclinical individual was negative by all RDTs at a
199	density of 39 parasites/µL by ddPCR. The clinical individual was RDT positive at a density of 136,000

- 200 parasites/µL.
- 201

## 202 Demographic risk factors for infection

Prevalence of subclinical infection, and test positivity rate peaked in children aged 5 to 15 years, both by qPCR and RDT (Table 1). Parasite densities decreased with age in clinical and subclinical infections (clinical: 9.7% decrease per year, P<0.001; subclinical: 4.6% decrease per year, P=0.003). As a result, RDT sensitivity tended to be higher in children than adults. Among clinical infections, sensitivity of the Biocredit RDT (any band) was 83.3% (150/180) in children below 15 years compared to 75.2% (100/133) in adults aged 15 and older (P=0.076). Among subclinical infections, sensitivity was 88.3% (53/61) in children and 66.5% (109/164) in adults (P=0.001).

210

No significant differences were observed between men and women in prevalence by qPCR or RDT, or
 RDT sensitivity (Table 1).

213

214

215 Discussion

216

This study found high sensitivity of a novel RDT for the diagnosis of *P. falciparum* infections in clinical and subclinical individuals in highly endemic setting in Burundi. Using a highly sensitive qPCR with a limit of

detection of <0.1 parasites/µL blood as gold standard, the RDT detected 80% of clinical and 72% of subclinical infections. The novel RDT performed substantially better compared to an established product that is used by malaria control programs in multiple countries.

222

223 Children are at highest risk of severe malaria, and in high transmission settings they are an important 224 reservoir of transmission. The convenience sampling on a market resulted in an underrepresentation of 225 children among subclinical individuals, with only 21% (100/468) study participants being below 15 years 226 of age, compared to approximately 45% in the general population [31]. In the small group of 61 children 227 that were positive by qPCR, the Biocredit RDT detected 88% of infections. Testing a group with an age 228 distribution more representative of the general population, it is expected that the overall sensitivity of the 229 RDT would be even higher than the 72% measured in the present study.

230

231 Compared to the established CareStart RDT, the LoD (defined as the parasite density where the 232 probability of a positive RDT is 95%) of the Biocredit RDT was 5-fold lower. The LoD of the Biocredit 233 HRP2-band only was 4-fold lower compared to the CareStart RDT, and the LoD of the Biocredit LDH-234 band only was moderately higher than the one of the CareStart. Of note, differences in the protocols used 235 for DNA extraction [28], and in the external standards used for qPCR [32], result in pronounced 236 differences in parasite quantification. Results from different studies are thus not directly comparable. We 237 extracted DNA from whole blood and used an extraction protocol that yielded fourfold more DNA than 238 another common protocol. Further, extraction from whole blood yielded tenfold more DNA than from DBS 239 [28]. Using these protocols resulted in high DNA recovery, and thus in higher LoDs.

240

No *hrp2* deletions were detected in the study population. Differences in the number of tests positive by LDH and HRP2 are thus fully caused by differences in the LoD of these targets. On the Biocredit RDT, HRP2 was substantially more sensitive than LDH. Where no deletions are present, HRP2-based RDTs remain the most sensitive diagnostic target for RDTs. Among clinical infections, sensitivity of the Biocredit LDH band was very similar to the AccessBio HRP2-based RDT (72% vs. 73%). Countries that switch to

non-HRP2-based RDTs due to high levels of deletion can expect similar sensitivity of diagnosis in clinical
 settings using the new test as with previous HRP2-based RDTs.

248

A high rate of false-positive RDTs was observed, and consequently a relatively low specificity. Antigens can persist after parasite clearance [33], though LDH levels were shown to follow parasite density closely [33]. Antigens persisting after treatment were shown to be a major cause of false-positive RDTs [34]. Recent treatment was not assessed in this study, thus this factor could not be assessed as cause for false-positive RDTs. False-positive RDTs can also be the result of non-*Plasmodium* infections [35, 36] and non-infectious diseases [37]. Most false-positive Biocredit RDTs were positive by one target only, either HRP2 or LDH. Using an RDT with two bands reduces specificity compared to a single-target test.

256

Half of the population in the study site in Burundi's north-west carried subclinical *P. falciparum* infections. These individuals are expected to be an important source of transmission [5-8]. Interventions targeting the asymptomatic reservoir might be needed to reduce transmission. The high sensitivity of the Biocredit RDT to diagnose subclinical infections opens up new avenues for malaria control, e.g. through mass screen and treat campaigns. Given the absence of *hrp2* deletions, HRP2-based diagnostic remains appropriate in the site of the current study. Surveillance for *hrp2* and *hrp3* deletions will be required in other sites across Burundi.

264

In conclusion, the Biocredit RDT offers high sensitivity for the diagnosis of clinical and subclinical infections. Parasite density distributions differ across transmission intensities, and more subpatent infections are generally observed as transmission declines [38, 39]. Studies in regions of medium and low transmission will be required to determine sensitivity and specificity in these populations.

269

#### 270 Acknowledgements

271 We thank all study participants and field teams.

- 272
- 273 Funding

- 274 This work was supported by the National Institutes of Health grant R21AI137891. The funders
- had no role in study design, data analysis, decision to publish, or preparation of the manuscript.

## 276 References

- 1. World Health Organisation. How malaria RDTs work. Available from:
- 278 https://www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-
- 279 diagnostic-tests/how-malaria-rdts-work.
- 280 2. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: Transforming Malaria Diagnosis,
- 281 but with Caveats. Trends Parasitol. 2020;36(2):112-26. Epub 2019/12/19. doi:
- 282 10.1016/j.pt.2019.12.004. PubMed PMID: 31848119.
- 283 3. World Health Organisation. World malaria report 2021. Geneva: 2021.
- 4. de Mast Q, Brouwers J, Syafruddin D, Bousema T, Baidjoe AY, de Groot PG, et al. Is
- asymptomatic malaria really asymptomatic? Hematological, vascular and inflammatory effects
- of asymptomatic malaria parasitemia. J Infection. 2015;71(5):587-96. doi:
- 287 10.1016/j.jinf.2015.08.005. PubMed PMID: WOS:000368479700011.
- 288 5. Goncalves BP, Kapulu MC, Sawa P, Guelbeogo WM, Tiono AB, Grignard L, et al.
- 289 Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of
- differing transmission intensity. Nat Commun. 2017;8(1):1133. Epub 2017/10/28. doi:
- 291 10.1038/s41467-017-01270-4. PubMed PMID: 29074880; PubMed Central PMCID:
- 292 PMCPMC5658399.
- 293 6. Ouedraogo AL, Goncalves BP, Gneme A, Wenger EA, Guelbeogo MW, Ouedraogo A, et
- al. Dynamics of the Human Infectious Reservoir for Malaria Determined by Mosquito Feeding
- Assays and Ultrasensitive Malaria Diagnosis in Burkina Faso. J Infect Dis. 2016;213(1):90-9. Epub
- 296 2015/07/05. doi: 10.1093/infdis/jiv370. PubMed PMID: 26142435.

297	7. Tadesse FG, Slater HC, Chali W, Teelen K, Lanke K, Belachew M, et al. The Relative			
298	Contribution of Symptomatic and Asymptomatic Plasmodium vivax and Plasmodium falciparum			
299	Infections to the Infectious Reservoir in a Low-Endemic Setting in Ethiopia. Clin Infect Dis.			
300	2018;66(12):1883-91. Epub 2018/01/06. doi: 10.1093/cid/cix1123. PubMed PMID: 29304258.			
301	8. Sumner KM, Freedman E, Abel L, Obala A, Pence BW, Wesolowski A, et al. Genotyping			
302	cognate Plasmodium falciparum in humans and mosquitoes to estimate onward transmission of			
303	asymptomatic infections. Nat Commun. 2021;12(1):909. Epub 2021/02/12. doi:			
304	10.1038/s41467-021-21269-2. PubMed PMID: 33568678; PubMed Central PMCID:			
305	PMCPMC7875998.			
306	9. Scott CA, Yeshiwondim AK, Serda B, Guinovart C, Tesfay BH, Agmas A, et al. Mass testing			
307	and treatment for malaria in low transmission areas in Amhara Region, Ethiopia. Malar J.			
308	2016;15:305. Epub 2016/06/04. doi: 10.1186/s12936-016-1333-3. PubMed PMID: 27255330;			
309	PubMed Central PMCID: PMCPMC4890322.			
310	10. Samuels AM, Odero NA, Odongo W, Otieno K, Were V, Shi YP, et al. Impact of			
311	Community-Based Mass Testing and Treatment on Malaria Infection Prevalence in a High-			
312	Transmission Area of Western Kenya: A Cluster Randomized Controlled Trial. Clin Infect Dis.			
313	2021;72(11):1927-35. Epub 2020/04/24. doi: 10.1093/cid/ciaa471. PubMed PMID: 32324850.			
314	11. Stuck L, Fakih BS, Al-Mafazy AH, Hofmann NE, Holzschuh A, Grossenbacher B, et al.			
315	Malaria infection prevalence and sensitivity of reactive case detection in Zanzibar. Int J Infect			
316	Dis. 2020;97:337-46. Epub 2020/06/14. doi: 10.1016/j.ijid.2020.06.017. PubMed PMID:			
317	32534138.			

318	12.	Searle KM, Katowa B, Musonda M, Pringle JC, Hamapumbu H, Matoba J, et al. Sustained			
319	Malari	a Transmission despite Reactive Screen-and-Treat in a Low-Transmission Area of			
320	Southe	ern Zambia. Am J Trop Med Hyg. 2020;104(2):671-9. Epub 2020/11/26. doi:			
321	10.426	9/ajtmh.20-0947. PubMed PMID: 33236715; PubMed Central PMCID: PMCPMC7866307.			
322	13.	Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large			
323	propor	tion of P. falciparum isolates in the Amazon region of Peru lack pfhrp2 and pfhrp3:			
324	implica	ations for malaria rapid diagnostic tests. PLoS One. 2010;5(1):e8091. Epub 2010/01/30.			
325	doi: 10.1371/journal.pone.0008091. PubMed PMID: 20111602; PubMed Central PMCID:				
326	PMCPMC2810332.				
327	14.	Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major Threat			
328	to Mal	aria Control Programs by Plasmodium falciparum Lacking Histidine-Rich Protein 2,			
329	Eritrea	. Emerg Infect Dis. 2018;24(3):462-70. Epub 2018/02/21. doi: 10.3201/eid2403.171723.			
330	PubMe	ed PMID: 29460730; PubMed Central PMCID: PMCPMC5823352.			
331	15.	Golassa L, Messele A, Amambua-Ngwa A, Swedberg G. High prevalence and extended			
332	deletic	ons in Plasmodium falciparum hrp2/3 genomic loci in Ethiopia. PLoS One.			
333	2020;1	.5(11):e0241807. Epub 2020/11/06. doi: 10.1371/journal.pone.0241807. PubMed PMID:			
334	33152	025; PubMed Central PMCID: PMCPMC7644029 adherence to PLOS ONE policies on data			
335	or mat	erials sharing.			
336	16.	Iriart X, Menard S, Chauvin P, Mohamed HS, Charpentier E, Mohamed MA, et al.			
337	Misdia	gnosis of imported falciparum malaria from African areas due to an increased prevalence			
338	of pfhr	p2/pfhrp3 gene deletion: the Djibouti case. Emerg Microbes Infect. 2020;9(1):1984-7.			

339 Epub 2020/09/02. doi: 10.1080/22221751.2020.1815590. PubMed PMID: 32869688; PubMed
340 Central PMCID: PMCPMC7534257.

- 17. Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. Pfhrp2-Deleted
- 342 Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-
- 343 sectional Survey. J Infect Dis. 2016. doi: 10.1093/infdis/jiw538. PubMed PMID: 28177502.
- 344 18. Amoah LE, Abankwa J, Oppong A. Plasmodium falciparum histidine rich protein-2
- 345 diversity and the implications for PfHRP 2: based malaria rapid diagnostic tests in Ghana. Malar
- 346 J. 2016;15:101. Epub 2016/02/20. doi: 10.1186/s12936-016-1159-z. PubMed PMID: 26891848;
- 347 PubMed Central PMCID: PMCPMC4759916.
- 348 19. Li B, Sun Z, Li X, Li X, Wang H, Chen W, et al. Performance of pfHRP2 versus pLDH
- 349 antigen rapid diagnostic tests for the detection of Plasmodium falciparum: a systematic review

350 and meta-analysis. Arch Med Sci. 2017;13(3):541-9. Epub 2017/05/17. doi:

351 10.5114/aoms.2017.67279. PubMed PMID: 28507567; PubMed Central PMCID:

352 PMCPMC5420633.

353 20. World Health Organisation. Response plan to *pfhrp2* gene deletions. Geneva: 2019.

254 21. Lok P, Dijk S. Malaria outbreak in Burundi reaches epidemic levels with 5.7 million

infected this year. BMJ. 2019;366:l5104. Epub 2019/08/11. doi: 10.1136/bmj.l5104. PubMed
PMID: 31399412.

- 357 22. Sinzinkayo D, Baza D, Gnanguenon V, Koepfli C. The lead-up to epidemic transmission:
- malaria trends and control interventions in Burundi 2000 to 2019. Malar J. 2021;20(1):298.
- 359 Epub 2021/07/04. doi: 10.1186/s12936-021-03830-y. PubMed PMID: 34215270; PubMed
- 360 Central PMCID: PMCPMC8249825.

- 361 23. World Health Organisation. Selecting and procuring malaria RDTs 2022 [cited 2022 April
- 362 12]. Available from: <u>https://www.who.int/teams/global-malaria-programme/case-</u>
- 363 management/diagnosis/rapid-diagnostic-tests/selection-and-procurement.
- 364 24. Maltha J, Gillet P, Bottieau E, Cnops L, van Esbroeck M, Jacobs J. Evaluation of a rapid
- 365 diagnostic test (CareStart Malaria HRP-2/pLDH (Pf/pan) Combo Test) for the diagnosis of
- 366 malaria in a reference setting. Malar J. 2010;9:171. Epub 2010/06/23. doi: 10.1186/1475-2875-
- 367 9-171. PubMed PMID: 20565816; PubMed Central PMCID: PMCPMC2906498.
- 368 25. Moges B, Amare B, Belyhun Y, Tekeste Z, Gizachew M, Workineh M, et al. Comparison of
- 369 CareStart HRP2/pLDH COMBO rapid malaria test with light microscopy in north-west Ethiopia.
- 370 Malar J. 2012;11:234. Epub 2012/07/24. doi: 10.1186/1475-2875-11-234. PubMed PMID:
- 371 22818643; PubMed Central PMCID: PMCPMC3411439.
- 372 26. World Health Organisation. Malaria rapid diagnostic test performance: results of WHO
- 373 product testing of malaria RDTs: round 8 (2016–2018). Geneva: 2018 978-92-4-151496-5.
- 27. Teh RN, Sumbele IUN, Asoba Nkeudem G, Meduke DN, Ojong ST, Kimbi HK. Concurrence
- 375 of CareStart Malaria HRP2 RDT with microscopy in population screening for Plasmodium
- 376 falciparum infection in the Mount Cameroon area: predictors for RDT positivity. Trop Med
- 377 Health. 2019;47:17. Epub 2019/03/15. doi: 10.1186/s41182-019-0145-x. PubMed PMID:
- 378 30867636; PubMed Central PMCID: PMCPMC6397448.
- 379 28. Holzschuh A, Koepfli C. Tenfold difference in DNA recovery rate: systematic comparison
- of whole blood vs. dried blood spot sample collection for malaria molecular surveillance. Malar
- 381 J. 2022;21(1):88. Epub 2022/03/17. doi: 10.1186/s12936-022-04122-9. PubMed PMID:
- 382 35292038.

- 383 29. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
- 384 detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS
- 385 Med. 2015;12(3):e1001788. Epub 2015/03/04. doi: 10.1371/journal.pmed.1001788. PubMed
- 386 PMID: 25734259; PubMed Central PMCID: PMCPMC4348198.
- 387 30. Vera-Arias CA, Holzschuh A, Oduma CO, Badu K, Abdul-Hakim M, Yukich J, et al.
- 388 Plasmodium falciparum hrp2 and hrp3 gene deletion status in Africa and South America by
- 389 highly sensitive and specific digital PCR. 2021. doi: 10.1101/2021.06.01.21258117.
- 390 31. United Nations Department of Economic and Social Affairs PD. World Population
- 391 Prospects 2019, Volume II: Demographic Profiles: Burundi 2019. Available from:
- 392 https://population.un.org/wpp/Graphs/1 Demographic%20Profiles/Burundi.pdf.
- 393 32. Koepfli C, Nguitragool W, Hofmann NE, Robinson LJ, Ome-Kaius M, Sattabongkot J, et al.
- 394 Sensitive and accurate quantification of human malaria parasites using droplet digital PCR
- 395 (ddPCR). Sci Rep. 2016;6:39183. Epub 2016/12/17. doi: 10.1038/srep39183. PubMed PMID:
- 396 27982132; PubMed Central PMCID: PMCPMC5159915.
- 397 33. Jang IK, Tyler A, Lyman C, Kahn M, Kalnoky M, Rek JC, et al. Simultaneous Quantification
- 398 of Plasmodium Antigens and Host Factor C-Reactive Protein in Asymptomatic Individuals with
- 399 Confirmed Malaria by Use of a Novel Multiplex Immunoassay. J Clin Microbiol. 2019;57(1). Epub
- 400 2018/11/09. doi: 10.1128/JCM.00948-18. PubMed PMID: 30404944; PubMed Central PMCID:
- 401 PMCPMC6322473.
- 402 34. Hosch S, Yoboue CA, Donfack OT, Guirou EA, Dangy JP, Mpina M, et al. Analysis of
- 403 nucleic acids extracted from rapid diagnostic tests reveals a significant proportion of false
- 404 positive test results associated with recent malaria treatment. Malar J. 2022;21(1):23. Epub

405 2022/01/26. doi: 10.1186/s12936-022-04043-7. PubMed PMID: 35073934; PubMed Central
406 PMCID: PMCPMC8785039.

- 407 35. Meatherall B, Preston K, Pillai DR. False positive malaria rapid diagnostic test in
- 408 returning traveler with typhoid fever. BMC Infect Dis. 2014;14:377. Epub 2014/07/10. doi:
- 409 10.1186/1471-2334-14-377. PubMed PMID: 25005493; PubMed Central PMCID:
- 410 PMCPMC4094604.
- 411 36. Gatton ML, Ciketic S, Barnwell JW, Cheng Q, Chiodini PL, Incardona S, et al. An
- 412 assessment of false positive rates for malaria rapid diagnostic tests caused by non-Plasmodium
- 413 infectious agents and immunological factors. PLoS One. 2018;13(5):e0197395. Epub
- 414 2018/05/15. doi: 10.1371/journal.pone.0197395. PubMed PMID: 29758050; PubMed Central
- 415 PMCID: PMCPMC5951549.
- 416 37. Lee JH, Jang JW, Cho CH, Kim JY, Han ET, Yun SG, et al. False-positive results for rapid
- 417 diagnostic tests for malaria in patients with rheumatoid factor. J Clin Microbiol.
- 418 2014;52(10):3784-7. Epub 2014/07/25. doi: 10.1128/JCM.01797-14. PubMed PMID: 25056333;
- 419 PubMed Central PMCID: PMCPMC4187788.
- 420 38. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability,
- 421 transmissibility and public health relevance. Nat Rev Microbiol. 2014;12(12):833-40. doi:
- 422 10.1038/nrmicro3364. PubMed PMID: 25329408.
- 423 39. Koepfli C, Ome-Kaius M, Jally S, Malau E, Maripal S, Ginny J, et al. Sustained Malaria
- 424 Control Over an 8-Year Period in Papua New Guinea: The Challenge of Low-Density
- 425 Asymptomatic Plasmodium Infections. J Infect Dis. 2017;216(11):1434-43. Epub 2017/10/14.

# 426 doi: 10.1093/infdis/jix507. PubMed PMID: 29029179; PubMed Central PMCID:

# 427 PMCPMC5853328.